stoxline Quote Chart Rank Option Currency Glossary
Virpax Pharmaceuticals, Inc. (VRPX)
3.51  0.458 (15.01%)    03-01 15:58
Open: 3.2
High: 3.7064
Volume: 39,434
Pre. Close: 3.052
Low: 3.0001
Market Cap: 4(M)
Technical analysis
2024-03-01 4:56:03 PM
Short term     
Mid term     
Targets 6-month :  4.32 1-year :  5.05
Resists First :  3.7 Second :  4.32
Pivot price 0.54
Supports First :  1.58 Second :  0.27
MAs MA(5) :  0.95 MA(20) :  0.5
MA(100) :  0.5 MA(250) :  0.71
MACD MACD :  0.2 Signal :  0
%K %D K(14,3) :  51.2 D(3) :  35.6
RSI RSI(14): 95.6
52-week High :  3.7 Low :  0.23
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VRPX ] has closed above the upper band by 43.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 1546% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.71 - 3.73 3.73 - 3.74
Low: 2.96 - 2.98 2.98 - 3
Close: 3.48 - 3.51 3.51 - 3.54
Company Description

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Headline News

Tue, 27 Feb 2024
Virpax Pharmaceuticals Announces Reverse Stock Split to Meet Nasdaq Requirements - Best Stocks

Tue, 27 Feb 2024
Virpax Pharmaceuticals announces 1-for-10 reverse stock split By -

Tue, 27 Feb 2024
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price - Yahoo Finance

Tue, 27 Feb 2024
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex ... - Yahoo Finance

Fri, 15 Dec 2023
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.15% By -

Thu, 14 Dec 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.43% By -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 12 (M)
Shares Float 9 (M)
Held by Insiders 49 (%)
Held by Institutions 3.2 (%)
Shares Short 71 (K)
Shares Short P.Month 92 (K)
Stock Financials
EPS -1.17
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.56
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -49.9 %
Return on Equity (ttm) -105 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -3
PEG Ratio 0
Price to Book value 6.26
Price to Sales 0
Price to Cash Flow -4.89
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android